India’s CDMO and CRDMO sectors are positioned for sustained growth in FY26, with India Ratings and Research (Ind-Ra) highlighting the impact of strategic capital investments and global supply chain transformations. The report underscores how companies in these sectors are capitalizing on the trend of pharmaceutical firms diversifying their supply chain away from China, while also leveraging India’s cost-efficient operations and skilled workforce. Nishith Sanghvi, Director at Ind-Ra, emphasizes that CDMO players are benefiting from supply chain rebalancing efforts, while CRDMOs are gaining momentum from securing significant contracts with major pharmaceutical companies.
Ind-Ra’s assessment of the sector’s financial health reveals a positive outlook, with 67% of portfolio entities rated in the ‘A’ category and the remainder in the ‘AA’ category. Notably, there have been upgrades within the sector due to improved financial metrics, underscoring the improved performance of these entities. The report forecasts revenue growth and margin expansion across the rated portfolio, supported by ongoing investments in capacity and technology. Additionally, the sector’s net leverage is expected to remain manageable, backed by healthier EBITDA margins and operational efficiencies.
While the sector witnessed significant investment in preceding years, there is now a shift towards more targeted and strategic capital expenditures. Companies are directing their investments towards enhancing niche capabilities such as peptides, antibody-drug conjugates, and advanced processes like flow chemistry and biocatalysis. This focused approach to capital allocation reflects a balance between growth ambitions and maintaining profitability, ensuring sustainable growth in the long term.
Ind-Ra’s analysis also highlights the increasing trend of global pharmaceutical companies outsourcing research and manufacturing activities. The report predicts a steady rise in R&D spending by pharmaceutical and biotech firms, with outsourcing accounting for a growing share of this expenditure. This shift is translating into heightened interest in Indian CDMO/CRDMO players, particularly from regions like the US, Europe, and Japan. The emphasis on integrated service providers with end-to-end capabilities and competitive pricing structures is driving this outsourcing momentum towards Indian firms.
The global supply chain diversification, fueled by strategies like China+1, is opening up new opportunities for Indian players in the CDMO sector. Even a slight shift in procurement away from Chinese suppliers can significantly impact Indian companies’ order books, leading to enhanced pipelines and accelerated capacity utilization. Despite inherent risks in the biotech landscape, Ind-Ra remains optimistic about the sector’s growth prospects, underpinned by long-term contracts, outsourcing trends, and prudent investment strategies. The focus on optimizing assets and maintaining financial discipline is expected to further bolster the sector’s credit profiles.
Key Takeaways:
– India’s CDMO and CRDMO sectors are set for continued growth in FY26, driven by global supply chain realignments and strategic investments.
– Companies in these sectors are benefiting from pharmaceutical firms diversifying away from China and tapping into India’s cost-effective operations.
– Strategic capital expenditures towards niche capabilities and advanced processes are enhancing the sector’s growth potential while maintaining profitability.
– The outsourcing momentum in the pharmaceutical industry is creating opportunities for Indian CDMO/CRDMO players, particularly from key markets like the US, Europe, and Japan.
Tags: antibody-drug conjugates, regulatory, biotech
Read more on businessworld.in